News
JD Wetherspoon today said warm weather boosted trading after reporting a 5.1% rise in like-for-like sales for the 12 weeks to Sunday. The group, which operates 794 pubs, added that profits are in line ...
The enterprise suite introduces four key AI agents – finance, payments, accounting and project management – each designed to ...
Find insight on Bruker, Sartorius, Sarepta and more in the latest Market Talks covering Health Care.
GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...
This summary highlights significant events in the health sector, including Johnson & Johnson's profit boost from Darzalex, safety concerns for GSK's cancer drug, refugee malnutrition in Gaza, KKR's ...
Hosted on MSN1mon
GSK (GSK) is a Top-Ranked Value Stock: Should You Buy?For new and old investors, taking full advantage of the stock market and investing with confidence are common ... which is more than double the S&P 500's performance over the same time frame. However, ...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Investing.com -- Berenberg has lowered its rating on GSK plc (LON: GSK) to Hold from Buy, a move driven by the stock’s strong year-to-date (YTD) performance and an expected pause in investor ...
Investing.com -- Berenberg has lowered its rating on GSK plc (LON:GSK) to Hold from Buy, a move driven by the stock’s strong year-to-date (YTD) performance and an expected pause in investor ...
GSK Turnover, Net Profit Expected to Rise; Weaker Vaccine Performance in Focus -- Earnings Preview Published: April 28, 2025, 9:23 a.m. ET Share Resize ...
GSK lifts long-term sales targets on new drug pipeline It came as the boss of the London-listed firm cheered an ‘excellent’ performance in 2024.
Graham Parry, an analyst from Bank of America Securities, maintained the Sell rating on GlaxoSmithKline (GSK – Research Report). The associated price target was lowered to p1,415.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results